Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU,China,Feb. 6,2025-- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co.,Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody